Publications by authors named "N Joseph-Ridge"
Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel.
View Article and Find Full Text PDFEffects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Arthritis Rheum
November 2008
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of febuxostat compared to allopurinol and placebo in treating hyperuricemia and gout among over 1,000 participants, including those with renal issues.
- Participants were randomly assigned to receive different doses of febuxostat, allopurinol, or placebo for 28 weeks, with results showing that febuxostat significantly reduced serum urate levels compared to allopurinol and placebo.
- Despite general safety across groups, febuxostat was associated with more incidences of gout flares and some specific side effects like diarrhea and dizziness at higher doses, yet it proved to be more effective overall in managing serum urate levels.
Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase, which is currently being developed for the management of hyperuricemia in patients with gout. The effect of age and gender on the pharmacokinetics, pharmacodynamics, and safety of once-daily oral febuxostat 80 mg was assessed in healthy male and female subjects after 7 days. Following multiple dosing with febuxostat, there were no statistically significant differences in the plasma or urinary pharmacokinetic or pharmacodynamic parameters between subjects aged 18 to 40 years and >or=65 years.
View Article and Find Full Text PDFDeterminants of the clinical outcomes of gout during the first year of urate-lowering therapy.
Nucleosides Nucleotides Nucleic Acids
June 2008
Clinical benefit early in urate-lowering treatment of gout is difficult to document. We examined data from 1,832 gouty subjects treated with either urate-lowering agents or placebo to identify determinants of gout flare incidence and tophus size during year 1 of treatment. Reductions from pretreatment serum urate levels influenced flare frequency and tophus size, but the effect of urate level on flare incidence was biphasic.
View Article and Find Full Text PDFUnlabelled: What is already known about this subject. Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase. What this study adds.
View Article and Find Full Text PDF